Exact Mass: 495.1457
Exact Mass Matches: 495.1457
Found 331 metabolites which its exact mass value is equals to given mass value 495.1457
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Sodium folinate
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AF - Detoxifying agents for antineoplastic treatment
Isometamidium chloride
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent
Morphine dinicotinate
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics
2,4(1H,3H)-Pyrimidinedione, 3-((2R)-2-amino-2-phenylethyl)-1-((2,6-difluorophenyl)methyl)-5-(2-fluoro-3-methoxyphenyl)-6-methyl-
Nikkomycin
D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D004791 - Enzyme Inhibitors
3-Azetidinecarboxamide, 1-(7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo(1,5-a)-1,3,5-triazin-4-yl)-3-(ethylamino)-
(9S,10R,12R)-2,3,9,10,11,12-Hexahydro-10-methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl ester
2-[(2S*,3R*,4S*)-3-ethenyl-2-(beta-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2H-pyran-4-yl]ethyl pyridine-3-carboxylate|tripterospermumcin A
N-(2-beta-D-glucopyranosyl-5-hydroxysalicyl)-5-hydroxy-6-methoxyanthranilic acid methyl ester
KT5823
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
Cys Cys Asp Arg
Cys Cys Arg Asp
Cys Asp Cys Arg
Cys Asp Lys Met
Cys Asp Met Lys
Cys Asp Met Gln
Cys Asp Gln Met
Cys Asp Arg Cys
Cys Glu Met Asn
Cys Glu Asn Met
Cys Gly Met Trp
Cys Gly Trp Met
Cys Lys Asp Met
Cys Lys Met Asp
Cys Met Asp Lys
Cys Met Asp Gln
Cys Met Glu Asn
Cys Met Gly Trp
Cys Met Lys Asp
Cys Met Asn Glu
Cys Met Gln Asp
Cys Met Arg Ser
Cys Met Ser Arg
Cys Met Trp Gly
Cys Asn Glu Met
Cys Asn Met Glu
Cys Asn Pro Tyr
Cys Asn Tyr Pro
Cys Pro Asn Tyr
Cys Pro Tyr Asn
Cys Gln Asp Met
Cys Gln Met Asp
Cys Arg Cys Asp
Cys Arg Asp Cys
Cys Arg Met Ser
Cys Arg Ser Met
Cys Ser Met Arg
Cys Ser Arg Met
Cys Ser Thr Trp
Cys Ser Trp Thr
Cys Thr Ser Trp
Cys Thr Trp Ser
Cys Trp Gly Met
Cys Trp Met Gly
Cys Trp Ser Thr
Cys Trp Thr Ser
Cys Tyr Asn Pro
Cys Tyr Pro Asn
Asp Cys Cys Arg
Asp Cys Lys Met
Asp Cys Met Lys
Asp Cys Met Gln
Asp Cys Gln Met
Asp Cys Arg Cys
Asp Lys Cys Met
Asp Lys Met Cys
Asp Met Cys Lys
Asp Met Cys Gln
Asp Met Lys Cys
Asp Met Gln Cys
Asp Gln Cys Met
Asp Gln Met Cys
Asp Arg Cys Cys
Glu Cys Met Asn
Glu Cys Asn Met
Glu Met Cys Asn
Glu Met Asn Cys
Glu Asn Cys Met
Glu Asn Met Cys
Gly Cys Met Trp
Gly Cys Trp Met
Gly Met Cys Trp
Gly Met Trp Cys
Gly Trp Cys Met
Gly Trp Met Cys
Lys Cys Asp Met
Lys Cys Met Asp
Lys Asp Cys Met
Lys Asp Met Cys
Lys Met Cys Asp
Lys Met Asp Cys
Met Cys Asp Lys
Met Cys Asp Gln
Met Cys Glu Asn
Met Cys Gly Trp
Met Cys Lys Asp
Met Cys Asn Glu
Met Cys Gln Asp
Met Cys Arg Ser
Met Cys Ser Arg
Met Cys Trp Gly
Met Asp Cys Lys
Met Asp Cys Gln
Met Asp Lys Cys
Met Asp Gln Cys
Met Glu Cys Asn
Met Glu Asn Cys
Met Gly Cys Trp
Met Gly Trp Cys
Met Lys Cys Asp
Met Lys Asp Cys
Met Met Asn Thr
Met Met Gln Ser
Met Met Ser Gln
Met Met Thr Asn
Met Asn Cys Glu
Met Asn Glu Cys
Met Asn Met Thr
Met Asn Thr Met
Met Gln Cys Asp
Met Gln Asp Cys
Met Gln Met Ser
Met Gln Ser Met
Met Arg Cys Ser
Met Arg Ser Cys
Met Ser Cys Arg
Met Ser Met Gln
Met Ser Gln Met
Met Ser Arg Cys
Met Thr Met Asn
Met Thr Asn Met
Met Trp Cys Gly
Met Trp Gly Cys
Asn Cys Glu Met
Asn Cys Met Glu
Asn Cys Pro Tyr
Asn Cys Tyr Pro
Asn Glu Cys Met
Asn Glu Met Cys
Asn Met Cys Glu
Asn Met Glu Cys
Asn Met Met Thr
Asn Met Thr Met
Asn Pro Cys Tyr
Asn Pro Tyr Cys
Asn Thr Met Met
Asn Tyr Cys Pro
Asn Tyr Pro Cys
Pro Cys Asn Tyr
Pro Cys Tyr Asn
Pro Asn Cys Tyr
Pro Asn Tyr Cys
Pro Tyr Cys Asn
Pro Tyr Asn Cys
Gln Cys Asp Met
Gln Cys Met Asp
Gln Asp Cys Met
Gln Asp Met Cys
Gln Met Cys Asp
Gln Met Asp Cys
Gln Met Met Ser
Gln Met Ser Met
Gln Ser Met Met
Arg Cys Cys Asp
Arg Cys Asp Cys
Arg Cys Met Ser
Arg Cys Ser Met
Arg Asp Cys Cys
Arg Met Cys Ser
Arg Met Ser Cys
Arg Ser Cys Met
Arg Ser Met Cys
Ser Cys Met Arg
Ser Cys Arg Met
Ser Cys Thr Trp
Ser Cys Trp Thr
Ser Met Cys Arg
Ser Met Met Gln
Ser Met Gln Met
Ser Met Arg Cys
Ser Gln Met Met
Ser Arg Cys Met
Ser Arg Met Cys
Ser Thr Cys Trp
Ser Thr Trp Cys
Ser Trp Cys Thr
Ser Trp Thr Cys
Thr Cys Ser Trp
Thr Cys Trp Ser
Thr Met Met Asn
Thr Met Asn Met
Thr Asn Met Met
Thr Ser Cys Trp
Thr Ser Trp Cys
Thr Trp Cys Ser
Thr Trp Ser Cys
Trp Cys Gly Met
Trp Cys Met Gly
Trp Cys Ser Thr
Trp Cys Thr Ser
Trp Gly Cys Met
Trp Gly Met Cys
Trp Met Cys Gly
Trp Met Gly Cys
Trp Ser Cys Thr
Trp Ser Thr Cys
Trp Thr Cys Ser
Trp Thr Ser Cys
Tyr Cys Asn Pro
Tyr Cys Pro Asn
Tyr Asn Cys Pro
Tyr Asn Pro Cys
Tyr Pro Cys Asn
Tyr Pro Asn Cys
KT 5823
1,2-dihydro-6-hydroxy-3,4-dimethyl-2-oxo-5-[[4-(phenylazo)phenyl]azo]-1,3-bipyridinium chloride
Nicomorphine
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AA - Natural opium alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
(R)-4-tert-Butyl-2-[(R)-2-(bis(1-phenyl)-phosphino)ferrocen-1-yl]oxazoline
2-Methyl-5-[(4-phenyl-1-piperazinyl)-(3,4,5-trimethoxyphenyl)methyl]-6-thiazolo[3,2-b][1,2,4]triazolol
Nikkomycin Z
A uridine-based nucleoside-peptide antibiotic which inhibits fungal chitin biosynthesis by inhibiting chitin synthase. D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D004791 - Enzyme Inhibitors
2,4(1H,3H)-Pyrimidinedione, 3-((2R)-2-amino-2-phenylethyl)-1-((2,6-difluorophenyl)methyl)-5-(2-fluoro-3-methoxyphenyl)-6-methyl-
(2S)-2-[[(2S,3S,4S)-2-azaniumyl-4-hydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutanoyl]amino]-2-[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]acetate
D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D004791 - Enzyme Inhibitors
2-amino-3-hydroxy-4-methylbenzoyl-AMP(1-)
An organophosphate oxoanion obtained by deprotonation of the phosphate OH group of 2-amino-3-hydroxy-4-methylbenzoyl-AMP; the major species at pH 7.3.
mycophenolic acid O-acyl-glucuronide(1-)
A carbohydrate acid derivative anion that is the conjugate base of mycophenolic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(2S,3R,4S,5S,6R)-2-[(1S,2R,5S,6S)-2,6-dihydroxy-3-(hydroxymethyl)-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]cyclohex-3-en-1-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-(1H-indol-3-ylmethylcarbamothioylsulfanyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-(6-chloro-2-phenylpyrimidin-4-yl)sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
Isometamidium chloride
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent
2-chloro-N-(2,3-dihydro-1H-inden-5-yl)-5-[(4-phenyl-1-piperazinyl)sulfonyl]benzamide
(2R)-2-[[(2R,3R,4R)-2-amino-4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxobutyl]amino]-2-[(2S,3R,4S,5S)-5-(2,4-dioxo-1-pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]acetic acid
[4-[2-(4-Methoxyphenyl)-5-phenyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]-(3-thiophenyl)methanone
1-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methyl]-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-3-piperidinecarboxamide
1-[(2S,3R,6S)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3,4-dichlorophenyl)urea
1-[(2R,3R,6R)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3,4-dichlorophenyl)urea
3-chloro-N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
1-[(2S,3S,6R)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3,4-dichlorophenyl)urea
N-[[(2R,3R)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
3-chloro-N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
N-[(3,4-dichlorophenyl)methyl]-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]acetamide
3-chloro-N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
N-[(3,4-dichlorophenyl)methyl]-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]acetamide
N-[(3,4-dichlorophenyl)methyl]-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]acetamide
methyl (1S,9R,10R,11R)-10-(hydroxymethyl)-12-(2-methylphenyl)sulfonyl-6-oxo-5-pyridin-3-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
N-[[(2S,3R)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2R,3R)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
3-chloro-N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
3-chloro-N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
2-chloro-N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
2-chloro-N-[(5R,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
2-chloro-N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
4-chloro-N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
4-chloro-N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
N-[(3,4-dichlorophenyl)methyl]-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]acetamide
N-[(3,4-dichlorophenyl)methyl]-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]acetamide
1-[(2S,3R,6R)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3,4-dichlorophenyl)urea
1-[(2S,3S,6S)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3,4-dichlorophenyl)urea
3,5-dichloro-N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[(4-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[(4-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[(4-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[(4-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]benzamide
methyl (1R,9S,10S,11S)-10-(hydroxymethyl)-12-(2-methylphenyl)sulfonyl-6-oxo-5-pyridin-3-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
4-[(3aR,4R,9bR)-4-(hydroxymethyl)-1-[(1-methyl-4-imidazolyl)sulfonyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
4-[(3aS,4R,9bS)-4-(hydroxymethyl)-1-[(1-methyl-4-imidazolyl)sulfonyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
3-[4-[(1S,5R)-3-(3-chlorophenyl)sulfonyl-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]-N,N-dimethylbenzamide
N-[[(2S,3S)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3S)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2R,3S)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3R)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
3-chloro-N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
3-chloro-N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
2-chloro-N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
2-chloro-N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
2-chloro-N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
2-chloro-N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
4-chloro-N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
4-chloro-N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
4-chloro-N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
4-chloro-N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
N-[(3,4-dichlorophenyl)methyl]-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]acetamide
N-[(3,4-dichlorophenyl)methyl]-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]acetamide
N-[(3,4-dichlorophenyl)methyl]-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]acetamide
1-[(2R,3S,6R)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3,4-dichlorophenyl)urea
1-[(2R,3S,6S)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3,4-dichlorophenyl)urea
1-[(2R,3R,6S)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(3,4-dichlorophenyl)urea
3,5-dichloro-N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[(4-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[(4-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[(4-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[(4-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]benzamide
4-[(3aR,4S,9bR)-4-(hydroxymethyl)-1-[(1-methyl-4-imidazolyl)sulfonyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
4-[(3aS,4S,9bS)-4-(hydroxymethyl)-1-[(1-methyl-4-imidazolyl)sulfonyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
Anti-inflammatory agent 35
Anti-inflammatory agent 35 (compound 5a27) is an orally active curcumin analogue with anti-inflammatory activity. Anti-inflammatory agent 35 blocks mitogen-activated protein kinase (MAPK) signaling and p65 nuclear translocation of NF-kB. Anti-inflammatory agent 35 also inhibits yellow neutrophil infiltration and pro-inflammatory cytokine production. Anti-inflammatory agent 35 significantly attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI) in vivo[1].
IPI-9119
IPI-9119 is an orally active, selective and irreversible FASN inhibitor with an IC50 of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models[1][2].
R 59-022 (hydrochloride)
R 59-022 (DKGI-I) hydrochloride is a DGK inhibitor (IC50: 2.8 μM). R 59-022 hydrochloride inhibits the phosphorylation of OAG to OAPA. R 59-022 hydrochloride is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 hydrochloride potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils[1][2][3][4].